Related Experiment Video

Updated: Jul 3, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors

Josep M Cruzado1

  • 1Nephrology Department, Bellvitge Hospital, Feixa Llarga s/n. 08907 L'Hospitalet de Llobregat, Barcelona, Spain. 27541jcg@comb.es

Transplantation Reviews (Orlando, Fla.)
|July 18, 2008
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise in treating diseases like cancer and may help prevent cardiovascular issues, obesity, and diabetes in organ transplant patients.

Area of Science:

  • Biomedical Science
  • Pharmacology
  • Transplantation Medicine

Background:

  • Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, integrating nutrient and hormonal signals.
  • mTOR inhibitors are emerging as crucial therapeutics for major human diseases including obesity, diabetes, atherosclerosis, and cancer.
  • Organ transplant recipients face increased incidence of these diseases, impacting transplant success.

Purpose of the Study:

  • To explore the potential of mTOR inhibitors in preventing cardiovascular diseases, obesity, and diabetes in organ transplant recipients.
  • To leverage the existing expertise of transplant teams in managing mTOR inhibitors.

Main Methods:

  • Review of preliminary data on mTOR inhibitor efficacy.
  • Analysis of clinical observations within transplant populations.

Main Results:

  • Preliminary data indicate mTOR inhibitors are effective in reducing posttransplant malignancy.
  • Transplant teams possess significant experience with mTOR inhibitors for managing acute rejection and nephrotoxicity.

Conclusions:

  • Transplant teams are uniquely positioned to investigate the role of mTOR inhibitors in preventing post-transplant cardiovascular diseases, obesity, and diabetes.
  • Further research is warranted to establish the efficacy of mTOR inhibitors for these conditions in transplant patients.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...